Nano in Davos: Health & The Fourth Industrial Revolution

Published

This week, Nano traveled to Davos for the 2019 World Economic Forum. One of this year’s discussion themes was the “Fourth Industrial Revolution,” which refers to the increasing overlap between technology and physical human life.

The Fourth Industrial Revolution represents a critical juncture where, as technologies like artificial intelligence and IoT become more prevalent, organizations and governments need to lay the groundwork for governing their use and managing the resulting societal transitions. Throughout the week, there was a lot of discussion about the ethics of intersecting technology and humanity, the future of jobs in an increasingly automated world and the possibilities for large-scale change across a number of industries.

The below video produced by the World Economic Forum is a great primer on the concept of the Fourth Industrial Revolution:

 

As part of this important discussion, Nano’s CEO Steve Papermaster spoke alongside Leonie Hill Capital CEO Arun Kant about how the Fourth Industrial Revolution is poised to be a game-changer for human health.

 

“Cloud computing, coupled with the advent of smart phones and structures like the app store, have lifted the capacity and output of the tech and software industry by several hundred thousand-fold. We will do the same for health.” 

-Steve Papermaster, CEO of Nano at Digital Davos

 

The conversation covered the need to harness emerging technologies for innovation in healthcare as other industries like transportation and communication have done over the last decade – and noted that healthcare is a notoriously slow-moving industry.

“But as I always say, ‘the elephant moves slowly,’” said Arun. “Being a start-up, Nano can move faster.”

We look forward to sharing a full video of the conversation in the coming days.

Nano’s CEO to Speak About the Future of Health in Davos

Published

Nano’s CEO, Steve Papermaster, will be interviewed alongside Leonie Hill Capital CEO Arun Kant by TechCrunch Editor Mike Butcher during the World Economic Forum in Davos. The two will discuss what could be healthcare’s “Uber moment” amid exciting advancements in technology like IoT and artificial intelligence.

The conversation will take place on Thursday, January 24th at 1 p.m. CET as part of the Davos Digital Forum located at Promenade 69.

News from the G7 Summit You May Have Missed: World Leaders Commit to Fighting Antibiotic Resistance

Published

Q&A with Maryn McKenna

Last month’s G7 Summit produced headlines covering subjects from political scandal to trade policy. But one critical outcome you may have missed is the G7’s commitment to holistically fighting antibiotic resistance, as outlined in the summit’s full communique. We caught up with Maryn McKenna between book tours, scientific meetings and reporting assignments to get a handle on the importance of this commitment by world leaders and the progress it could represent.

Continue reading

The Greatest Threat to Human Health Hasn’t Changed in 100 Years

Published

greatest health threat

Q&A with Dr. Amesh Adalja

Our world today is pretty different than it was 100 years ago. We have smart phones, Bluetooth, the internet, virtual reality and 3D printers. You can change the temperature in your home from your office at the press of a button or start your car’s engine from across the parking lot. So why does one of the biggest threats to human health remain unchanged?

Continue reading

How Nano Aims to Disrupt Healthcare – An Interview with CNNMoney

Published

Last week, Nano CEO Steve Papermaster appeared on CNNMoney Switzerland to discuss how Nano Vision hopes to boost health and economic progress by developing a new technology platform to monitor and analyze health threats and creating a global marketplace for data. “As our Cure Platform develops, it will enable many other companies to grow, to find new kinds of cures and new kinds of products to bring to the market,” said Steve. “And that’s good for everybody. It’s good from a health standpoint and it’s good from an economic standpoint.”

Continue reading

Why Are Superbugs Still Such a Threat?

Published

rise of super bugs Nano Vision

An alarming public health crisis is on the horizon: the rise of superbugs, or bacterial infections that are resistant to antibiotic treatment. Antibiotics have been essential to our society since their discovery in 1928. It’s estimated that penicillin, the first antibiotic, has saved up to 200 million lives. In addition to fighting common illnesses, antibiotics have been key to developing many modern surgical procedures, as they help surgical wounds resist bacterial infection.

Continue reading

Nano and TechCrunch Fireside Chat

Published

Nano Chairman and CEO Steve Papermaster and TechCrunch Editor-at-Large Mike Butcher recently sat down together in London to discuss Nano Vision’s mission, platform development and initial cure acceleration targets. View the video or read the full transcript below.

Continue reading

Citizen Science and the Future of Global Health

Published

Citizen Scientist

Science is reserved for people in white lab coats with expensive degrees and sophisticated equipment, right? Wrong. Citizen scientists are ordinary people who participate in science through data collection, scientific study participation or even just support of scientific projects or endeavors. Citizen scientists play a critical role in the healthcare and research worlds and should be empowered to contribute however they can. Continue reading

Breaking Down Barriers: Why We Need to Decentralize Data

Published

Data is one of our most valuable commodities – it gives us critical information about our world and holds the key to cures for diseases. It’s also very expensive to create.

Companies, universities and other institutions invest enormous amounts of time and money in research programs or clinical trials to produce important data with the hope that it will have an impact on health through the creation of new treatments or cures. Unfortunately, after having invested substantially in research and trials , these stakeholders  are not incentivized to share this data with others. Continue reading